Vaccine Development

BioSante Pharmaceuticals announces positive trial results for tuberculosis vaccine

Published in TB and Outbreaks Week, June 18th, 2002

BioSante Pharmaceuticals, Inc. announced successful results of a preclinical trial demonstrating the effectiveness of its calcium phosphate nanoparticulate (CAP) vaccine adjuvant and delivery system (Bio-Vant) in a tuberculosis (TB) vaccine. The results were presented in Prague, Czech Republic, at the Immunopotentiators in Modern Medicine meeting.

In the reported study, a tuberculosis subunit vaccine was combined with Bio-Vant in a proprietary formulation developed by scientists at BioSante's research center in Smyrna, Georgia, and immune response was tested in a mouse model. The studies were designed to test the effects of Bio-Vant on the immunogenicity elicited...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry